DDInter8 DDInter1658
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Abiraterone {u} (Compound) resembles {v} (Compound) Testosterone
Abiraterone {u} (Compound) treats {v} (Disease) prostate cancer
Abiraterone {u} (Compound) binds {v} (Gene) ABCC1
Abiraterone {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Torasemide
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Abiraterone (Compound) resembles Testosterone (Compound)
Abiraterone (Compound) treats prostate cancer (Disease)
Abiraterone (Compound) binds ABCC1 (Gene)
Abiraterone (Compound) causes Hypokalaemia (Side Effect)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Torasemide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Abiraterone may lead to a major life threatening interaction when taken with Dofetilide
Abiraterone may lead to a major life threatening interaction when taken with Ivabradine